New combo therapy aims to shrink head and neck tumors before surgery

NCT ID NCT07371234

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing whether combining low-dose radiotherapy with the immunotherapy drug Toripalimab before surgery can improve outcomes for people with advanced head and neck squamous cell carcinoma. About 22 participants will receive two cycles of the combination, then undergo surgery. The main goal is to see how many patients have a major reduction in tumor cells after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Toripalimab (an anti-PD-1 immunotherapy drug) and low-dose radiotherapy
What this could lead to
If successful, this combination could shrink tumors before surgery, potentially improving survival and reducing recurrence for people with advanced head and neck cancer.
What could go wrong
This is a small, early-phase trial with only 22 participants, so results may not apply to everyone. The treatment may cause side effects from immunotherapy or radiation, and it's not yet proven to be better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Fifth Affiliated Hospital,Sun Yat-sen University

    RECRUITING

    Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.